Mar. 5 - Track 2: AI in Clinical Decision Support & RWE Track

Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen

Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes

Sessions:

• TBA